Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says
Merck's (MRK) data from a phase 2b study evaluating tulisokibart in hidradenitis suppurativa looks s
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo